Anti-TNF therapy

DRUG5 trials

Sponsors

Barts & The London NHS Trust, Takeda, University Hospital, Bordeaux, Connecticut Children's Medical Center, IRCCS Ospedale San Raffaele

Conditions

Colitis, UlcerativeCrohn DiseaseCrohn Disease (CD)Inflammatory Bowel DiseasesRheumatoid ArthritisUlcerative Colitis (UC)

Phase 3

Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Active, not recruitingNCT04870203

University Hospital, BordeauxRheumatoid Arthritis

Start: 2021-07-15End: 2027-03-01Updated: 2026-03-17

Phase 4

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

RecruitingNCT05781152

Connecticut Children's Medical CenterCrohn Disease

Start: 2023-06-10End: 2029-07-01Target: 900Updated: 2026-05-27

Unknown Phase

Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Rheumatoid Arthritis

Barts & The London NHS TrustRheumatoid Arthritis

Start: 2010-10-31End: 2018-04-30Target: 24Updated: 2015-08-19

Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

CompletedNCT03090139

TakedaColitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

Start: 2017-03-28End: 2018-06-13Updated: 2018-06-26

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

RecruitingNCT06896305

IRCCS Ospedale San RaffaeleCrohn Disease (CD), Ulcerative Colitis (UC)

Start: 2025-05-22End: 2027-10-01Target: 80Updated: 2026-01-22

Related Papers

Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study

Gastroenterología y Hepatología (English Edition)2024-01-01

Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.

2023-04-143 citations

Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study

BMC Gastroenterology2022-02-0414 citations

P020 Incidence of Suboptimal Response to First-Line Anti-TNF Therapy in Patients with IBD in Argentina: Results from the EXPLORE Study

The American Journal of Gastroenterology2020-12-01

Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study.

2020-06-1718 citations